FibroGen Inc. (FGEN)

41.01
0.40 0.97
NASDAQ : Health Technology
Prev Close 41.41
Open 41.43
Day Low/High 40.16 / 41.57
52 Wk Low/High 33.51 / 61.95
Volume 465.02K
Avg Volume 579.70K
Exchange NASDAQ
Shares Outstanding 86.92M
Market Cap 3.63B
EPS -1.00
P/E Ratio 77.96
Div & Yield N.A. (N.A)

Latest News

Roxadustat Approved In China For Treatment Of Anemia In Chronic Kidney Disease Patients Not Receiving Dialysis

Roxadustat Approved In China For Treatment Of Anemia In Chronic Kidney Disease Patients Not Receiving Dialysis

SAN FRANCISCO, Aug. 21, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATVI, FGEN Downgrades: BRKS, CSOD, KVHI, LRN, MDRX, PKX, PNM, TS Initiations: JRSH Read on to get TheStreet Quant Ratings' detailed report:

FibroGen Reports Second Quarter 2019 Financial Results

FibroGen Reports Second Quarter 2019 Financial Results

— On Track to Submit U.S.

CORRECTION - FibroGen To Report Second Quarter 2019 Financial Results On Thursday, August 8, 2019

CORRECTION - FibroGen To Report Second Quarter 2019 Financial Results On Thursday, August 8, 2019

SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by FibroGen, Inc (NASDAQ: FGEN) we are advised by the company the "Live (U.

FibroGen To Report Second Quarter 2019 Financial Results On Thursday, August 8, 2019

FibroGen To Report Second Quarter 2019 Financial Results On Thursday, August 8, 2019

SAN FRANCISCO, Aug. 01, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc.

Roxadustat China Phase 3 Trial For Treatment Of Anemia In Chronic Kidney Disease Patients Not On Dialysis Published In The New England Journal Of Medicine (NEJM)

Roxadustat China Phase 3 Trial For Treatment Of Anemia In Chronic Kidney Disease Patients Not On Dialysis Published In The New England Journal Of Medicine (NEJM)

-- One of Two Concurrent Publications of Roxadustat China Phase 3 Results in The New England Journal of Medicine --

The New England Journal Of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results For The Treatment Of Anemia In Chronic Kidney Disease Patients Receiving Dialysis

The New England Journal Of Medicine (NEJM) Publishes Roxadustat China Phase 3 Results For The Treatment Of Anemia In Chronic Kidney Disease Patients Receiving Dialysis

-- One of Two Concurrent Publications of Roxadustat China Phase 3 Results in The New England Journal of Medicine -- SAN FRANCISCO, July 24, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc.

FibroGen Announces First Patient Dosed In ZEPHYRUS, A Phase 3 Clinical Trial Of Pamrevlumab For The Treatment Of Patients With Idiopathic Pulmonary Fibrosis

FibroGen Announces First Patient Dosed In ZEPHYRUS, A Phase 3 Clinical Trial Of Pamrevlumab For The Treatment Of Patients With Idiopathic Pulmonary Fibrosis

SAN FRANCISCO, July 22, 2019 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN), today announced dosing of the first patient in the ZEPHYRUS Phase 3 clinical study of pamrevlumab in patients with idiopathic pulmonary fibrosis (IPF).

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ACU, DGICA, ELSE, MSBI, PLAG, STRS Downgrades: BKE, CMRE, DGII, ETSY, FGEN, OXY, TTMI, WCC Initiations: CEPU, GHG Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: FGEN, GOLF, HNGR, MO, NOMD, NRE, PYX Downgrades: ANIK, BDC, CRHM, ETM, RUN, SEAS, TKC, WBA, XXII Initiations: ADT, EYE Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: CTB, FII, GVA, MIME, PETX Downgrades: DF, FGEN, MUX, NXGN, PANL, TAIT Initiations: DESP Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: EOG, FGEN, GASS, GHC, SATS Downgrades: ALB, CFBK, CLI, DISCB, FORM, HCCI, IONS, KOP, LTC, MNRO, PNTR, SRE Initiations: FRAC, JELD, REVG Read on to get TheStreet Quant Ratings' detailed report:

FibroGen To Report Fourth Quarter And Full Year 2017 Financial Results On Tuesday, February 27, 2018

FibroGen To Report Fourth Quarter And Full Year 2017 Financial Results On Tuesday, February 27, 2018

Conference Call and Audio Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Jobs Plus Earnings Equal Buys: Cramer's 'Mad Money' Recap (Friday 11/3/17)

Will the benign backdrop continue next week? Cramer has a defensive game plan, in case earnings chill the market.

FibroGen To Report Third Quarter Financial Results On Wednesday, November 8, 2017

FibroGen To Report Third Quarter Financial Results On Wednesday, November 8, 2017

Conference Call and Webcast Scheduled for 5:00 p.m. ET (2:00 p.m. PT)

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Get Ready for an Earnings Onslaught: Cramer's 'Mad Money' Recap (Friday 10/20/17)

Jim Cramer's game plan is jam-packed for next week; this is the heart of earnings season.

Magellan Midstream, Walt Disney, Align Technology: 'Mad Money' Lightning Round

Magellan Midstream, Walt Disney, Align Technology: 'Mad Money' Lightning Round

Jim Cramer is bullish on Magellan Midstream, Walt Disney, Align Technology and Schlumberger.

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

Spectrum Shares Surge on Data for Lung Cancer Drug -- Biotech Movers

The Henderson, Nev.-based company said interim data from a Phase 2 study showed an objective response rate of 73%.

Kratos Defense, Fibrogen, Nike: 'Mad Money' Lightning Round

Kratos Defense, Fibrogen, Nike: 'Mad Money' Lightning Round

A roundup of stocks Mad Money viewers asked Jim Cramer about Tuesday.

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Activists Can Boost Shares: Cramer's 'Mad Money' Recap (Tuesday 10/10/17)

Activist investors have helped smaller shareholders win higher valuations for their holdings.

The Flippers Are at Work and the Bears Are Hopeful

The Flippers Are at Work and the Bears Are Hopeful

Apple and its suppliers are dragging the market down.

TheStreet Quant Rating: C (Hold)